Effects of estrogen on brain development and neuroprotection--implications for negative symptoms in schizophrenia.
Increasing evidence during the last few years suggests that there are gender-specific differences in schizophrenia, influencing the age of onset, treatment outcome and the prevalence of negative symptoms. With respect to the latter in postmortem brain and cerebrospinal fluid of schizophrenic patients with negative symptoms a reduction of dopaminergic activity became evident. Measures of noradrenergic activity, dopamine beta-hydroxylase and the metabolite MHPG, appear to decrease with brain atrophy seen in patients with negative symptoms. Serotonergic activity tends to be low in patients with impaired cognitive function as is seen in negative schizophrenia. In these patients ventricular enlargement is associated with the severity of negative symptoms, low monoamine activity and low cerebral glucose metabolism. On the other hand atypical antipsychotic drugs that modulate also glutamate receptor activity, suggest an additional alternative mechanism of antipsychotic action beyond aminergic neurotransmitters. These drugs improve glutamatergic transmission and decrease negative symptoms; this suggests a glutamatergic deficiency as an extension of the dopamine model. The glutamate-dopamine interaction illustrates the importance of cross-talk between projections to the cortex, striatum, and lower brainstem for the expression of negative symptomatology. On the other hand, estradiol-17beta the most potent female sex hormone influences not only primary and secondary sexual characteristics but also embryonal and fetal growth as well as development of the brain aminergic networks, which are involved in schizophrenia. Estradiol-l7beta possesses neuroprotective properties, which are relevant for the course of schizophrenia and this may explain the pronounced gender differences with respect to progression and therapeutic response of schizophrenia. The present review attempts an update and synthesis of the information about the hormonal influence on neuronal pathways in negative symptoms of schizophrenia. It shows that estradiol-l7beta influences transporters and receptors as well as the morphological appearance of neuronal systems and that it may be an integral part of the neuroprotective system ameliorating schizophrenia.
Rao
M L
ML
Department of Psychiatry and Psychotherapy, Medical Department of the University of Bonn, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany. m.l.rao@uni-bonn.de
Kölsch
H
H
D015306:Biogenic Monoamines; D001921:Brain / Q000187:drug effects / Q000254:growth & development*; D003625:Data Collection; D004967:Estrogens / Q000494:pharmacology* / Q000502:physiology*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000502:physiology; D006801:Humans; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D012559:Schizophrenia / Q000503:physiopathology; D012565:Schizophrenic Psychology; D012727:Sex Characteristics
D015306:Biogenic Monoamines; D004967:Estrogens; D012739:Gonadal Steroid Hormones; D018696:Neuroprotective Agents